Clinical features, diagnosis, combined medical treatment, epidemiological characteristics and therapy of 26 confirmed COVID-19 cases.

Abstract

Background: Clinical features, diagnosis, medical treatment, epidemiological characteristics, and the therapy of 26 confirmed cases were analyzed to provide a scientific basis for formulating epidemic prevention with control strategies and measures. Methods: An epidemiological survey, clinical features, treatment guidelines were conducted for 26 patients, who were diagnosed with Corona Virus Disease-19 (COVID-19) and have been treated in The General Hospital since Jan. 2020 according to China national guideline for COVID-19. Results: The ratio of males to females were 3.25∶1.22, (84.62%) were more than 18 years old. There were 20 (76.92%) cases suffering from fever, 14 (53.85%) cases with weakness, and 8 (30.77%) with dry cough. Progressive muscle relaxation (PMR) therapy could help COVID-19 patients overcome anxiety and sleep problems, which may give a boost in their mental strength to fight against this COVID-19 during their stay in the isolation ward. In this study, both the clinical results and quality of evidence showed that Ribavirin, Lopinavir/Ritonavir, Moxifloxacin and Arbidol Hydrochloride combination with supportive drugs are probably major effective treatments. In the present pandemic situation, frontline physicians; who treat patients in a medical setting and evaluate prophylaxis for COVID-19 high-risk environments formed by large quarantined and isolated populations, are facing a lot of challenges. Conclusion: Most cases were males. The aged people group were at higher risk of the disease. Half of the cases were caused by living together and close contact with a patient. Different combination drugs use for COVID-19 is clinically successfully effective in published literature, including this study.